Press Release: DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC were progression free at 4.5 years1 AURIGA study shows higher rates of MRD negative conversion in subgroup patient populations disproportionately impacted by multiple myeloma2
Press Release: DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis - Newscast
Fri, 25 Apr 2025 05:00:00 GMT Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway ...
Tue, 15 Apr 2025 05:21:00 GMT Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net ...
Tue, 15 Apr 2025 04:21:00 GMT Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...
Mon, 14 Apr 2025 20:22:00 GMT Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...
Mon, 14 Apr 2025 17:00:00 GMT New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...
